Strong Industry Engagement Cognition Therapeutics actively participates in major healthcare and neuroscience conferences such as AAIC, AD/PD, and the Hanson Wade Neuroimmunology Drug Development Summit, indicating opportunities for industry partnerships and collaborations.
Promising Clinical Results Recent positive phase 2 trial results for Zervimesine (CT1812) in treating dementia with Lewy bodies and Alzheimer's disease suggest strong potential for expanding clinical trials and increasing adoption by healthcare providers.
Innovative Therapeutics The company's focus on developing oral drugs for neurodegenerative disorders positions it well to meet the growing demand for accessible and effective dementia therapies, opening avenues for licensing and distribution deals.
Financial Growth Potential With revenues between $10M and $25M and recent funding of $12M, Cognition Therapeutics is poised for growth, presenting opportunities for investment, strategic partnerships, and expanded R&D collaborations.
Market Focus Specializing in neurodegenerative disorders such as Alzheimer's and Lewy body dementia, the company offers targeted solutions that align with increasing market demand for specialized neurological treatments.
Cognition Therapeutics, Inc. uses 8 technology products and services including Modernizr, Elementor, Priority Hints, and more. Explore Cognition Therapeutics, Inc.'s tech stack below.
| Cognition Therapeutics, Inc. Email Formats | Percentage |
| FLast@cogrx.com | 49% |
| Last@cogrx.com | 1% |
| FMiddleLast@cogrx.com | 1% |
| FLast@cogrx.com | 49% |
Biotechnology ResearchNew York, United States11-50 Employees
Cognition Therapeutics, Inc. is a clinical stage company developing oral drugs for neurodegenerative disorders like Alzheimer's disease and dementia with Lewy bodies.
Company Overview
Media & News
Funding & FinancialsCognition Therapeutics, Inc. has raised a total of $12M of funding over 22 rounds. Their latest funding round was raised on Mar 11, 2024 in the amount of $12M.
Cognition Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M
Funding & FinancialsCognition Therapeutics, Inc. has raised a total of $12M of funding over 22 rounds. Their latest funding round was raised on Mar 11, 2024 in the amount of $12M.
Cognition Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com